IceCure Medical (ICCM) Expected to Announce Earnings on Wednesday

IceCure Medical (NASDAQ:ICCM) is expected to release its Q3 2025 results before the market opens on Wednesday, November 19th. Analysts expect IceCure Medical to post earnings of ($0.06) per share and revenue of $0.6260 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 10:00 AM ET.

IceCure Medical Stock Up 0.4%

Shares of ICCM stock opened at $0.71 on Monday. The business’s fifty day moving average is $0.89 and its 200-day moving average is $0.96. IceCure Medical has a 1 year low of $0.56 and a 1 year high of $1.66. The stock has a market cap of $48.97 million, a PE ratio of -4.46 and a beta of 0.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.88 and a current ratio of 1.18.

Analyst Ratings Changes

ICCM has been the subject of a number of recent analyst reports. Brookline Capital Management reaffirmed a “buy” rating on shares of IceCure Medical in a research note on Wednesday, August 13th. Loop Capital set a $2.77 price target on IceCure Medical in a research note on Wednesday, August 13th. HC Wainwright increased their price objective on IceCure Medical from $2.00 to $2.50 and gave the company a “buy” rating in a report on Tuesday, October 7th. Zacks Research lowered IceCure Medical from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $2.64.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.